Carel le Roux, MBChB, MSc, PhD - Beyond BMI: Transforming Modern Weight Management for Heart, Kidney, and Metabolic Health

Hannele Yki-Järvinen, MD, FRCP - MASH Matters – and It’s More Than Just a Metabolic Disease

Jun 9, 202625 minSummary

In this episode of PeerVoice Endocrinology & Metabolic Disorders Audio, Dr. Hannele Yki-Järvinen and Dr. Cyril Kaisi provide a comprehensive overview of metabolic dysfunction-associated steatohepatitis (MASH) and its critical intersection with type 2 diabetes and metabolic syndrome. The discussion emphasizes that MASH is far more than a localized liver condition; it is closely linked to insulin resistance, obesity, and cardiovascular risk. The experts detail the evolving diagnostic landscape, clarifying the definitions of metabolic dysfunction-associated steatotic liver disease (MASLD) and the pivotal role of liver fibrosis in predicting patient mortality. A key highlight is the shift toward non-invasive diagnostic tools, such as the FIB-4 index and vibration-controlled transient elastography (VCTE), which allow clinicians to identify high-risk patients efficiently. The conversation further explores recent advancements in pharmacological treatments, including Resmetiron and semaglutide, noting that liver biopsies are no longer strictly required to initiate these therapies. Ultimately, the hosts advocate for integrating liver health screening into routine endocrinology and diabetes care, urging clinicians to adopt structured, two-step diagnostic algorithms to ensure timely interventions and appropriate referrals for patients at risk of advanced fibrosis.